Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

74 BORTEZOMIB
(2006): San Miguel J+, Oncologist 11(1), 51
(2005): Dimopoulos MA+, Haematologica 90(12), 1655
(2005): Goy A+, J Clin Oncol 23(4), 667 (5%)
(2005): Richardson PG+, NEnglJMed352(24), 2487
(2004): Kondagunta GV+, J Clin Oncol 22(18), 3720 (53%)
Pain
(2004): Davis NB+, J Clin Oncol 22(1), 115
Upper respiratory infection (18%)
BOSENTAN
Trade name: Tracleer (Actelion)
Indications: Pulmonary arterial hypertension
Category: Endothelin receptor antagonist; Vasodilator
Half-life: ~5 hours
Clinically important, potentially hazardous interactions
with: atorvastatin, cyclosporine, fluvastatin, glibenclamide,
glyburide, itraconazole, ketoconazole, lovastatin, oral
contraceptives, simvastatin, St John’s wort, warfarin
Reactions
Skin
Edema (8%)
(2004): Dingemanse J+, Clin Pharmacokinet 43(15), 1089
Necrotizing vasculitis
(2004): Gasser S+, BMJ 329(7463), 430
Peripheral edema (8%)
Pruritus (4%)
Other
Hepatotoxicity
(2006): Suntharalingam J+, Vascul Pharmacol 44(6), 508
BOSWELLIA
Scientific names: Boswellia carterii; Boswellia commiphora;
Boswellia ovalifoliolata; Boswellia serrata
Family: Burseraceae
Trade and other common names: Boswellin; Frankincense;
Gum olibanum Ethiopia; Gum olibanum somalilands; Nopane;
Olibanum; Salai guggal; Shallaki
Category: Anti-inflammatory; Diuretic
Purported indications and other uses: Allergic rhinitis,
arthritis, asthma, atherosclerosis, chronic colitis, ulcerative colitis,
Crohn’s disease, peritumoral brain edema, rheumatism,
trypanosomiasis, ulcers
Half-life: N/A
Clinically important, potentially hazardous interactions
with: aspirin, ibuprofen, montelukast, naproxen
Reactions
Skin
Irritation
(1999): Buckle J, Altern Ther Health Med 5(5), 42
Rash (sic)
*Note: no interactions have been reported. The drugs listed may
interact
BOTULINUM TOXIN (A & B)
Trade names: Botox (Allergan); Dysport (Ipsen); Myobloc
(Solstice)
Indications: Blepharospasm, hemifacial spasm, spasmodic
torticollis, sialorrhea, hyperhidrosis, strabismus, oromandibular
dystonia, cervical dystonia, spasmodic dysphonia. Cosmetic
application for wrinkles
Category: Acetylcholine inhibitor; Neuromuscular blocker
Half-life: 3–6 months
Reactions
Skin
Acne
Allergic granulomatous angiitis (Churg–Strauss syndrome)
(2006): Ahbib S+, Ann Dermatol Venereol 133(1), 43
Allergic reactions (sic)
Depigmentation
(1999): Roehm PC+, J Neuroophthalmol 19(1), 7
Erythema multiforme
Hematomas
(1997): Heinen F+, Neuropediatrics 28(6), 307 (local)
(1997): Nussgens Z+, Graefes Arch Clin Exp Opthalmol
235(4), 197
Intertrigo
(2002): Madalinski MH+, Eur J Gastroenterol Hepatol 14(8), 853
(1 case)
Peripheral edema (1–10%)
Pruritus (1–10%)
Psoriasis
Purpura (1–10%)
Rash (sic)
(2005): Cote TR+, JAmAcadDermatol53(3), 407
Urticaria
Mucosal
Oral candidiasis
(2003): Dressler D+, Eur Neurol 49(1), 34
Stomatitis (1–10%)
Vulvovaginal candidiasis (1–10%)
Xerostomia (3–34%)
(2006): Dressler D+, Neurotox Res 9(2-3), 121
(2005): Comella CL+, Neurology 65(9), 1423
(2004): Brashear A+, Arch Phys Med Rehabil 85(5), 705
(2004): Fishman LM+, Am J Phys Med Rehabil 83(1), 42 (50%)
(2004): Ondo WG+, Neurology 62(1), 37 (3 cases)
(2004): Schwerin A+, Pediatr Neurol 31(2), 109 (10%)
(2003): Brashear A+, Arch Phys Med Rehabil 84(1), 103
(2003): Dressler D+, Eur Neurol 49(1), 34
Eyes
Conjunctivitis
(2006): Dressler D+, Neurotox Res 9(2-3), 121
Diplopia
(2006): Aristodemou P+, Ophthal Plast Reconstr Surg 22(2), 134
Ectropion
(1990): NIH Consensus Statement 8(8), 1
Entropion
Eyelid edema
(1990): NIH Consensus Statement 8(8), 1
Ptosis (14–20%)
(2005): Cote TR+, JAmAcadDermatol53(3), 407 (2 cases)
(2002): Molloy F, eMedicine Journal 3(2) (10%)
(1997): Nussgens Z+, Graefes Arch Clin Exp Ophthalmol
235(4), 197
(1990): NIH Consensus Statement 8(8), 1